RxDoctor Payments Data

Katherine Rabbio, PA

Physician Assistant · Grand Junction, CONPI 1902271786

Payments from drug & device makers

$5,602in general payments, 2019–2025

Across 288 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$852
  • Gilead$789
  • Johnson & Johnson$485
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$290
  • Regeneron Healthcare Solutions, Inc.$155
  • plus $962 from 17 others

What the payments were for

  • Food & beverage$5,44697%
  • Education$1563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,602 in reported general payments places this provider in the 95th percentile of 2,849 physician assistant providers in Colorado.

See all physician assistant providers in Colorado

Medicare billing

Part B allowed, 2024
$49,440
Medicare patients
307
Services billed
492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab21$558,726
CreonLipase/Protease/Amylase42$209,997
ZenpepLipase/Protease/Amylase22$157,911
XifaxanRifaximin31$85,051
Humira(Cf) PenAdalimumab13$84,652
LinzessLinaclotide61$52,017
Mesalamine56$28,732
MotegrityPrucalopride Succinate34$18,915
Mesalamine ErMesalamine30$16,213
TrulancePlecanatide23$12,640
Colestipol Hcl55$8,912
AprisoMesalamine13$6,525
Lubiprostone37$5,009
Dexlansoprazole DrDexlansoprazole15$3,703
Budesonide DrBudesonide41$2,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$485$558,72621 claims
AbbVieCreon, Linzess$2,067$262,014103 claims
Aimmune Therapeutics, Inc.Zenpep$64$157,91122 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Apriso$290$104,21667 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$852$18,91534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,849 physician assistant providers in Colorado.

Other physician assistant in Grand Junction

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →